Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors

Journal of Thoracic Oncology

Volumn 7, Issue 1, 2012, Pages 40-48

  Lazzari, Chiara ^a   Spreafico, Anna ^a   Bachi, Angela ^a   Roder, Heinrich ^b   Floriani, Irene ^c   Garavaglia, Daniela ^c   Cattaneo, Angela ^a   Grigorieva, Julia ^b   Viganò, Maria Grazia ^a   Sorlini, Cristina ^a   Ghio, Domenico ^a   Tsypin, Maxim ^b   Bulotta, Alessandra ^a   Bergamaschi, Luca ^a   Gregorc, Vanesa ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Biodesix   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Epidermal growth factor receptor tyrosine kinase inhibitors; Non small cell lung cancer; Proteomics; Resistance to epidermal growth factor tyrosine kinase inhibitor

Indexed keywords

GEFITINIB;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; DRUG WITHDRAWAL; FEMALE; GENE DELETION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84655167119     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182307f17     Document Type: Article

References (46)

1. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004;58:903-913. (Pubitemid 38221150)
2. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41:29-42.
3. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-1174.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21: 2237-2246. (Pubitemid 46621858)
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in ymptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158. (Pubitemid 37432975)
6. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537. (Pubitemid 41540110)
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
8. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-994. (Pubitemid 351398092)
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
10. Paez JG, JÄnne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
11. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26:1742-1751.
12. JÄnne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-smallcell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005;23:3227-3234. (Pubitemid 46211347)
13. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
14. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042. (Pubitemid 46631407)
15. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
16. Lee J. A randomized Phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first line treatment for never smokers with advanced or metastatic adenocarcinoma of the lung. Presented at World Conference of Lung Cancer 2009, Abstract PRS. 4.
17. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small- cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
18. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
19. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
20. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-smallcell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
21. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008;26: 4268-4275.
22. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433.
23. Bozzetti C, Tiseo M, Lagrasta C, et al. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol 2008;3:18-22.
24. Gow CH, Chang YL, Hsu YC, et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive nonsmall-cell lung cancer. Ann Oncol 2009;20:696-702.
25. Engelman JA, JÄnne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
26. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multi-cohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
27. Carbone D. Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib or placebo in the NCIC CTG BR.21 Trial. Presented at 2nd European Lung Cancer Conference, April 2010. J Thorac Oncol 2010;55:S80. Abstr. 2030.
28. Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 2010;19:358-365.
29. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010;69: 337-340.
30. Hirsch FR, Varella-Garcia M, McCoy C, et al. Increased EGFR gene copy number detected by FISH associates with increased sensitivity to gefitinib in patients with bronchioalveolar carcinoma subsets. J Clin Oncol 2005;23:2823.
31. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-762.
32. Gregorc V. Prospective studies with proteomic. Presented at 13th World Conference on Lung Cancer, San Francisco, 2009.
33. Hunsucker SW, Grigorieva J, Helfrich BA, et al. Pretreatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affects sensitivity of lung cancer cell lines to EGFR-TKIs. Presented at AACR meeting abstracts, April 2011.
34. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
35. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor- activating mutations. Cancer Res 2008;68:9479-9487.
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
37. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins. J Clin Invest 2008;118:2609-2619. (Pubitemid 351949788)
38. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008;68:8322-8332.
39. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
40. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010;5:169-178.
41. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-2075. (Pubitemid 351439466)
42. Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 2010;2:198-203.
43. Tortora G, Bianco R, Daniele G, et al. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumors and haematologic malignancies. Drug Resist Updat 2007;3:81-100. (Pubitemid 47031052)
44. Peebles KA, Lee JM, Mao JT, et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 2007;10:1405-1421. (Pubitemid 351826907)
45. Yao Z, Fenoglio S, Gao DC, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-15540.
46. Bivona TG, Hieronymus H, Parker J, et al. FAS and NF-kB signaling modulate dependence of lung cancers on mutant EGFR. Nature 2011; 7339:523-526.